Abstract
We agree with Hay and colleagues that, although neutropenia worries clinicians, it is often an unimportant finding and rarely requires treatment.1 Drug induced neutropenia is common in patients with rheumatic disease. We recognise that this is an increasing problem in primary care. It rarely leads to an alteration in the patient’s management, although it causes concern to non-specialists. We would like …